JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Journal of Clinical Oncology (JCO) Podcast
Release Date: 06/01/2026
pCR Rates and Predictors With THP in HER2-Positive Breast Cancer: EA1181/CompassHER2 pCR
Journal of Clinical Oncology (JCO) Podcast
What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on her article, “.” They examine differences in pCR by estrogen receptor status and the clinicopathologic and HER2DX features associated with response, while considering how these findings may inform treatment personalization as the trial’s 3-year recurrence-free survival data mature.
info_outline
JCO Article Insights: Long-Term Follow-Up of Weekly Cisplatin + RT in Postoperative HNC
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Jake New interviews Dr. Makoto Tahara about the JCO article "." They discuss clinical considerations for individualizing treatment schedules and impact of treatment schedule on toxicity and patient quality of life.
info_outline
Dexrazoxane and Long-Term Cardiac Function After Doxorubicin: Insights From COG ALTE11C2
Journal of Clinical Oncology (JCO) Podcast
How does dexrazoxane affect left ventricular function over time after doxorubicin treatment for childhood cancer? Host Dr. Davide Soldato sits down with Dr. Erin Mobley and Dr. Eric Chow to discuss their article, “” They examine the longitudinal echocardiographic findings, the durability of cardioprotection, and how dexrazoxane exposure might eventually inform cardiomyopathy risk stratification and
info_outline
Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. Vedang Murthy and host Davide Soldato discuss JCO article, "" and delve into trial design, results, clinical implications, and future directions in bladder cancer treatment.
info_outline
JCO Article Insights: Duvelisib in Patients with Relapsed or Refractory PTCL
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "," by Mehta-Shah and colleagues.
info_outline
Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
Journal of Clinical Oncology (JCO) Podcast
Guests Dr. Elise Park, Dr. Jamie Ostrov and host Dr. Davide Soldato discuss JCO article "" and their groundbreaking trial on virtual tobacco cessation treatment for cancer patients in community settings. LINK TO FULL TRANSCRIPT
info_outline
Phase 2 Study of Multi-Cancer Detection from Breath Samples
Journal of Clinical Oncology (JCO) Podcast
Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invasive cancer screening methods.
info_outline
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
Journal of Clinical Oncology (JCO) Podcast
JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O’Reilly discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "."
info_outlineJCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study."